Abiomed announced that it received Investigational Device Exemption, or IDE, approval from the FDA for the use of the new Impella RP, or Right-side Percutaneous, in a pivotal clinical study in the U.S. In the future, Abiomed plans to expand its clinical experience with the Impella RP through a pivotal biventricular "Bridge to Recovery" study, in combination with the Impella left-side devices.
There’s just about no tolerance left in America for wealthy people griping about their financial woes. But is it …